Pfizer reportedly nears deal with Allergan; health insurers are to blame for rising healthcare costs, according to report; a new fund seeks to invest in digital bio start-ups
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
Five things for pharma marketers to know: Thursday, November 5, 2015
Pfizer increases the financial assistance it gives to patients; Senate committee opens investigation into drug pricing; OptumRx reportedly stopped business with Philidor a year ago
Five things for pharma marketers to know: Monday, November 2, 2015
Shire said it will acquire Dyax, which markets Kalbitor; Citron doesn’t plan to release any additional allegations against Valeant; Myriad Genetics launches social-media campaign
Five things for pharma marketers to know: Friday, October 30, 2015
Valeant cuts ties with Philidor; federal officials arrest former Warner Chilcott president over kickback charges; researchers question accuracy of media report that describe drugs as miracles
Five things for pharma marketers to know: Thursday, October 29, 2015
Pfizer in merger talks with Allergan; comparative effectiveness council says PCSK9s aren’t worth the money; pharmacy tied to Valeant used “back-door” sales tactics
Five things for pharma marketers to know: Wednesday, October 28, 2015
Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy
Valeant subsidiary discloses subpoena over doctor payments